Medical Device Global Market Access

On June 5, 2026, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) updated its core guidance for Software as a Medical Device (SaMD). This episode breaks down the key changes, including new requirements for AI/ML validation, heightened cybersecurity expectations, and clarified classification rules. We explore how these updates will impact regulatory strategies, submission timelines, and wh...

This episode breaks down the US FDA's new draft guidance on AI-enabled medical device software, released on June 6, 2026. We explore the FDA's stricter requirements for algorithm transparency, data provenance, risk management, and real-world performance monitoring. We discuss how these changes impact pre-market submissions and post-market obligations for manufacturers and highlight the critical op...

The US FDA's June 3, 2026 draft guidance on manufacturer communications with payors marks a significant policy shift for the medical device industry. This episode breaks down how the guidance extends the safe harbor for sharing Healthcare Economic Information (HCEI) to medical devices and incorporates the Pre-Approval Information Exchange (PIE) Act. We discuss the practical implications for market...

The US FDA has released a new final guidance, effective June 4, 2026, exempting certain unclassified medical devices from 510(k) premarket notification. This episode explains what 'unclassified devices' are, how this policy streamlines their market access pathway, and the specific actions manufacturers should take to leverage this change while remaining compliant with FDA's General Controls. Key Q...

The European Union has extended the compliance deadline for the AI Act for high-risk medical devices and IVDs already regulated by the MDR and IVDR. A provisional agreement on the Digital Omnibus package has postponed the application date by two years to August 2, 2028. This episode explores what this delay means for manufacturers, how it impacts compliance strategies, and the practical steps regu...

The US FDA issued a final guidance on June 4, 2026, immediately exempting five unclassified medical device product codes from 510(k) premarket notification requirements. This episode details the guidance, 'Intent to Exempt Certain Unclassified Medical Devices from Premarket Notification Requirements,' explaining which manufacturers are affected, the scope of the FDA's enforcement discretion, and t...

This episode explores the China NMPA's new dynamic adjustment procedure for its Medical Device Classification Catalog, effective June 1, 2026. We discuss what this shift from a static to an evolving system means for manufacturers, including the impact of announcements No. 52 and No. 53, and the new obligation to continuously monitor for changes that could affect regulatory pathways, timelines, and...

The European Commission has adopted Implementing Regulation (EU) 2026/977, establishing harmonized and binding timelines for Notified Body conformity assessments under the MDR and IVDR. This episode details the new maximum timelines for key review stages—such as the 90-day limit for technical documentation assessment—and new rules for cost transparency. We explore how this regulation, adopted on M...

The UK's MHRA has published draft medical device regulations set for 2026, introducing a new standalone framework for Great Britain. This episode breaks down the most significant change: the International Reliance pathway, which will leverage approvals from the US, Canada, and Australia to streamline UK market access. We cover the critical June 19, 2026, deadline for the industry impact survey, ot...

In this episode, we break down Mexico's new comprehensive medical device labeling standard, NOM-137-SSA1-2025, published by the health regulator COFEPRIS. We explore the key changes from the previous 2008 version, including new definitions for 'component' and 'single-use device,' and the new mandate to include the intended use, manufacturing date, and catalog number directly on device labeling. We...

In this episode, we explore the U.S. FDA's significant new guidance on Human Factors Engineering (HFE) for medical devices. The host breaks down the new three-tiered, risk-based framework for HFE submissions, which impacts 510(k), De Novo, and PMA applications. We discuss the specific changes, who is most affected, the critical implementation deadline of January 1, 2027, and provide practical, act...

This episode details the critical EUDAMED deadline of May 28, 2026, when four key modules become mandatory for medical device and IVD manufacturers in the EU. We explain the immediate legal obligation to register all new MDR and IVDR devices in the UDI/Devices module before market placement. We also cover the mandatory registration for actors—manufacturers, authorized representatives, and importer...

This episode explores the future of the structural heart market, a key growth area in MedTech. We discuss the technological advancements in imaging, catheter tools, and procedural guidance that are shaping the industry. We analyze how leading companies like Edwards Lifesciences, Medtronic, Abbott, and Boston Scientific are moving beyond single implants to create comprehensive procedural ecosystems...

This episode explores the imminent commercialization of Brain-Computer Interface (BCI) technology, moving it from a futuristic concept to a medical reality by 2026. We examine the four critical non-technical hurdles the industry must overcome for successful global market access: establishing clear clinical utility, navigating the complex reimbursement landscape with payers like CMS, addressing pro...

This episode explores the future of AI in healthcare, focusing on whether ambient documentation and AI-powered charting will become standard clinical infrastructure by 2026. We weigh the technology's potential to reduce physician burnout and improve data quality against the significant barrier of provider trust, particularly concerning the accuracy of AI-generated notes in high-stakes medical envi...

This episode explores the critical challenge MedTech leaders face in 2026 regarding the safe implementation of AI chatbots in healthcare. We discuss how to develop a robust governance model that effectively balances the competing demands of innovation speed, user-friendliness, essential human oversight, and uncompromising patient safety to prevent misleading patients and clinicians. - How can MedT...

This episode explores the significant market shift toward molecular and genetic diagnostics projected for 2026. We analyze the key drivers behind this trend and outline how MedTech and IVD companies can create value in high-growth areas like oncology, infectious disease, personalized medicine, and the development of integrated data platforms that provide actionable clinical insights. - Why is diag...

This episode examines the critical threat facing the U.S. diagnostics industry due to flawed implementation of the Protecting Access to Medicare Act (PAMA). We explore how skewed data collection has led to severe reimbursement cuts, disproportionately impacting smaller, innovative labs. We discuss the 2026 outlook, the looming risk of market consolidation, and how this environment stifles investme...

This episode forecasts the state of medical technology mergers and acquisitions for 2026. We analyze whether the industry will see a return to large, transformative deals driven by the need to fill portfolio gaps in diagnostics, structural heart, and workflow assets, or if valuation discipline and integration risks will ensure the market remains focused on smaller, more selective acquisitions. - W...

This episode explores the significant impact that rising tariffs and supply-chain nationalism are projected to have on the medical technology industry by 2026. We dissect the four primary strategic responses available to MedTech firms: relocating production, diversifying sourcing networks, increasing prices, or absorbing shrinking profit margins. The host explains how these choices will be influen...

This episode examines the immense pressures facing medical device manufacturers from Europe's Medical Device Regulation (MDR) and In-Vitro Diagnostic Regulation (IVDR) leading up to 2026. We explore the two potential outcomes: widespread "portfolio pruning" and market consolidation due to high compliance costs and Notified Body bottlenecks, or the successful reduction of these pressures by regulat...

This episode delves into the upcoming 2026 Medical Device User Fee Amendments (MDUFA VI) negotiations and their profound impact on the U.S. medtech landscape. We explore how these negotiations will influence FDA review predictability, staffing stability, and fee structures, and what this means for the strategic planning of medical device companies, particularly startups and smaller innovators. - W...

This episode explores the prediction that by 2026, the primary obstacle for AI medical devices will shift from technical validation to securing financial reimbursement. We discuss why clear payment pathways, understandable coding logic, and compelling health economic outcome evidence are becoming more critical than algorithmic accuracy for commercial success. This is a crucial look at the strategi...

This episode explores the future of the diabetes technology market, examining the critical tension between rapid innovation and foundational regulatory challenges. We analyze whether the competitive landscape leading into 2026 will be defined more by exciting advancements like fully closed-loop systems and longer-wear sensors, or by persistent issues such as product recalls, complaint handling, an...

This episode explores the transformative potential of AI-enabled imaging and ultrasound tools designed for non-experts, set to reshape diagnostics by 2026. We dissect the four emerging business models—hardware, workflow software (SaMD), remote interpretation, and population-scale screening—and analyze the unique global regulatory, data privacy, and market access challenges associated with each. Di...